NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: SBC Medical Group's Q3 2025 Financial Performance and Expansion Strategy
TL;DR
SBC Medical's strategic pricing and expansion into Thailand positions investors for strong 2026 growth with improved profitability and international market entry.
SBC Medical increased net profit to $13 million through franchise expansion, pricing optimization, and cost reductions while maintaining a 72% customer repeat rate.
SBC Medical's expansion into Thailand brings advanced dermatological treatments to new markets, improving access to quality cosmetic care internationally.
SBC Medical is entering Thailand's $1.2 billion aesthetic market through a Bangkok clinic partnership while acquiring Waqoo for R&D synergies.
Found this article helpful?
Share it with your network and spread the knowledge!
SBC Medical reported $43 million in total revenue (down 18% year-over-year), net income of $13 million (up from $3 million last year), EBITDA of $17 million (up 12%), and an EBITDA margin of 38% compared to 28% in Q3 2024.
Revenue declined due to revised fee structures for clinic services, reduced procurement revenue from lower medical material orders, and discontinued clinic operation staff services, while profitability improved from reduced operating expenses and the absence of IPO-related and stock-based compensation expenses.
The company overhauled its pricing strategy through promotions and targeting more affluent customers, resulting in average revenue per visit increasing 6% sequentially to $298 and up 8.4% from Q1 2025.
The company is focusing on international expansion, specifically targeting Thailand as its next market, while continuing to grow its domestic presence with 258 locations (up 15% year-over-year) and pursuing multi-brand initiatives in dermatology.
Yoshiyuki Aikawa serves as Chairman and CEO and stated the company will 'continue to pursue sustainable growth toward 2026 by focusing on delivering high-quality solutions, advancing multi-brand initiatives, and building a stronger business foundation in overseas markets.'
The company ended the quarter with $127 million in cash and reported a 72% customer repeat rate, indicating strong financial health and customer loyalty heading into 2026.
While Q3 2025 revenue was 18% lower than Q3 2024, it was essentially unchanged from Q2 2025, showing stabilization due to new clinic openings and improved average revenue per patient visit.
The company has discontinued its staffing business, engaged in targeted divestitures to streamline operations, revised fee structures to attract more repeat customers, and shifted focus to franchise expansion and higher-value customer acquisition.
Curated from NewMediaWire
